procaine has been researched along with Injury, Myocardial Reperfusion in 30 studies
Procaine: A local anesthetic of the ester type that has a slow onset and a short duration of action. It is mainly used for infiltration anesthesia, peripheral nerve block, and spinal block. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1016).
procaine : A benzoate ester, formally the result of esterification of 4-aminobenzoic acid with 2-diethylaminoethanol but formed experimentally by reaction of ethyl 4-aminobenzoate with 2-diethylaminoethanol.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The reduction in hypothermia and ischaemia-induced reperfusion arrhythmias by the addition of sevoflurane to HTK solution may be related to the phosphorylation of Cx43 at serine 368." | 7.91 | Antiarrhythmic effect of sevoflurane as an additive to HTK solution on reperfusion arrhythmias induced by hypothermia and ischaemia is associated with the phosphorylation of connexin 43 at serine 368. ( Gao, H; Gao, J; Li, WC; Wang, ZJ, 2019) |
| "The reduction in hypothermia and ischaemia-induced reperfusion arrhythmias by the addition of sevoflurane to HTK solution may be related to the phosphorylation of Cx43 at serine 368." | 3.91 | Antiarrhythmic effect of sevoflurane as an additive to HTK solution on reperfusion arrhythmias induced by hypothermia and ischaemia is associated with the phosphorylation of connexin 43 at serine 368. ( Gao, H; Gao, J; Li, WC; Wang, ZJ, 2019) |
| " The purpose of this study was to evaluate clinical efficacy of the TWBC in combination with B-HTK for myocardial protection." | 2.69 | [Efficacy of terminal warm blood cardioplegia in combination with Bretschneider-HTK solution for myocardial protection]. ( Endoh, M; Hachida, M; Ishitoya, H; Kitamura, M; Koyanagi, H; Morishita, A, 1999) |
| "After selective cardiac arrest with Bretschneider, captopril-treated hearts showed improved hemodynamics compared to control and the other treatment groups." | 1.40 | Acute hemodynamic effects of angiotensin- converting enzyme inhibition after prolonged cardiac arrest with Bretschneider's solution. ( Dhein, S; Hoyer, A; Kempfert, J; Mohr, FW; Pritzwald-Stegmann, P, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (3.33) | 18.7374 |
| 1990's | 9 (30.00) | 18.2507 |
| 2000's | 5 (16.67) | 29.6817 |
| 2010's | 15 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wang, D | 1 |
| Zhang, X | 1 |
| Qu, D | 1 |
| Han, J | 1 |
| Meng, F | 1 |
| Xu, M | 1 |
| Zheng, Q | 1 |
| Schaefer, M | 1 |
| Gebhard, MM | 2 |
| Gross, W | 1 |
| Li, WC | 1 |
| Gao, H | 1 |
| Gao, J | 1 |
| Wang, ZJ | 1 |
| Qiang, Z | 1 |
| Yu, W | 1 |
| Yu, Y | 1 |
| Sung, SY | 1 |
| Lin, CY | 1 |
| Song, JY | 1 |
| Tsai, YT | 1 |
| Kao, CH | 1 |
| Lee, CY | 1 |
| Lin, YC | 1 |
| Hsu, PS | 1 |
| Tsai, CS | 1 |
| Hoyer, A | 2 |
| Kempfert, J | 2 |
| Pritzwald-Stegmann, P | 2 |
| Mohr, FW | 2 |
| Dhein, S | 2 |
| Chen, Y | 1 |
| Liu, J | 1 |
| Li, S | 1 |
| Yan, F | 1 |
| Xue, Q | 1 |
| Wang, H | 1 |
| Sun, P | 1 |
| Long, C | 1 |
| Aarsaether, E | 1 |
| Stenberg, TA | 1 |
| Jakobsen, Ø | 1 |
| Busund, R | 1 |
| Koch, A | 1 |
| Loganathan, S | 1 |
| Radovits, T | 1 |
| Sack, FU | 1 |
| Karck, M | 1 |
| Szabó, GB | 1 |
| Lee, S | 1 |
| Huang, CS | 1 |
| Kawamura, T | 1 |
| Shigemura, N | 1 |
| Stolz, DB | 1 |
| Billiar, TR | 1 |
| Luketich, JD | 1 |
| Nakao, A | 1 |
| Toyoda, Y | 1 |
| Wei, L | 2 |
| Wu, RB | 2 |
| Yang, CM | 2 |
| Zheng, SY | 2 |
| Yu, XY | 2 |
| Viana, FF | 1 |
| Shi, WY | 1 |
| Hayward, PA | 1 |
| Larobina, ME | 1 |
| Liskaser, F | 1 |
| Matalanis, G | 1 |
| Lima, ML | 1 |
| Fiorelli, AI | 1 |
| Vassallo, DV | 1 |
| Batista, PR | 1 |
| Simoes, FV | 1 |
| Fiorim, J | 1 |
| Stefanon, I | 1 |
| Pinheiro, BB | 1 |
| Stolf, NA | 1 |
| Gomes, OM | 1 |
| Trescher, K | 1 |
| Hasun, M | 1 |
| Baumgartner, A | 1 |
| Dietl, W | 1 |
| Wolfsberger, M | 1 |
| Hallström, S | 1 |
| Podesser, BK | 1 |
| Fuchs, F | 1 |
| Messmer, K | 1 |
| Kuppe, H | 1 |
| Habazettl, H | 1 |
| Ebel, D | 1 |
| Preckel, B | 3 |
| You, A | 1 |
| Müllenheim, J | 1 |
| Schlack, W | 3 |
| Thämer, V | 3 |
| Möllhoff, T | 1 |
| Sukehiro, S | 1 |
| Borgers, M | 1 |
| Vandeplassche, G | 1 |
| Van Belle, H | 1 |
| Van Aken, H | 1 |
| Flameng, W | 1 |
| Chong, YS | 1 |
| Cottier, DS | 1 |
| Gavin, JB | 1 |
| Hachida, M | 2 |
| Ookado, A | 1 |
| Nonoyama, M | 1 |
| Koyanagi, H | 2 |
| Mustonen, PK | 1 |
| Hippeläinen, MJ | 1 |
| Pöyhönen, MJ | 1 |
| Rehnberg, LS | 1 |
| Sakata, J | 1 |
| Morishita, K | 1 |
| Ito, T | 1 |
| Koshino, T | 1 |
| Kazui, T | 1 |
| Abe, T | 1 |
| Morishita, A | 1 |
| Kitamura, M | 1 |
| Ishitoya, H | 1 |
| Endoh, M | 1 |
| Keeling, IM | 1 |
| Obermayr, RP | 1 |
| Schneider, B | 1 |
| Spieckermann, PG | 1 |
| Schmiedl, A | 2 |
| Richter, J | 2 |
| Schnabel, PA | 2 |
| Bach, F | 1 |
| Bartels, U | 1 |
| Ramsauer, B | 1 |
| Bretschneider, HJ | 1 |
| Tutterová, M | 1 |
| Vavrínková, H | 1 |
| Janata, V | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Custodiol-HTK Solution as a Cardioplegic Agent- A Prospective Non-Inferiority Randomized Clinical Trial[NCT01681095] | Phase 2 | 110 participants (Actual) | Interventional | 2012-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Number of participants with all-cause mortality AS reported in the Society of Thoracic Surgeons (STS) database after 30 days postoperative (NCT01681095)
Timeframe: 30 days post procedure
| Intervention | participants (Number) |
|---|---|
| Cardioplegia: Custodiol HTK Solution | 0 |
| Cold Blood Cardioplegia | 0 |
CK-MB measured 24 hours post-operatively (NCT01681095)
Timeframe: 24 hours post procedure
| Intervention | ng/mL (Mean) |
|---|---|
| Cardioplegia: Custodiol HTK Solution | 20 |
| Cold Blood Cardioplegia | 24 |
CK-MB measured 48 hours post-operatively (NCT01681095)
Timeframe: 48 hours post procedure
| Intervention | ng/mL (Mean) |
|---|---|
| Cardioplegia: Custodiol HTK Solution | 6.0 |
| Cold Blood Cardioplegia | 7.8 |
CK-MB measured pre-operatively (NCT01681095)
Timeframe: pre-operative
| Intervention | ng/mL (Mean) |
|---|---|
| Cardioplegia: Custodiol HTK Solution | 1.9 |
| Cold Blood Cardioplegia | 2.6 |
Number of participants with new or worsening of cardiac dysrhythmias (NCT01681095)
Timeframe: up to 36 hrs post surgery
| Intervention | participants (Number) |
|---|---|
| Cardioplegia: Custodiol HTK Solution | 24 |
| Cold Blood Cardioplegia | 30 |
Troponin-I measured 24 hours post-operative (NCT01681095)
Timeframe: 24 hours post procedure
| Intervention | ng/mL (Mean) |
|---|---|
| Cardioplegia: Custodiol HTK Solution | 5.7 |
| Cold Blood Cardioplegia | 7.8 |
Troponin-I measured 48 hours post-operative (NCT01681095)
Timeframe: 48 hours post procedure
| Intervention | ng/mL (Mean) |
|---|---|
| Cardioplegia: Custodiol HTK Solution | 3.0 |
| Cold Blood Cardioplegia | 4.8 |
Troponin-I measured pre-operatively (NCT01681095)
Timeframe: pre-operatively
| Intervention | ng/mL (Mean) |
|---|---|
| Cardioplegia: Custodiol HTK Solution | .03 |
| Cold Blood Cardioplegia | .03 |
Number of participants with cardiovascular-related mortality AS reported in the Society of Thoracic Surgeons (STS) database after 30 days postoperative (NCT01681095)
Timeframe: 30 days post procedure
| Intervention | participants (Number) |
|---|---|
| Cardioplegia: Custodiol HTK Solution | 0 |
| Cold Blood Cardioplegia | 0 |
Creatine phosphokinase MB isoenzyme (CK-MB) difference from baseline 7 hours post surgery (NCT01681095)
Timeframe: Baseline and 7 hours post surgery
| Intervention | ng/mL (Median) |
|---|---|
| Cardioplegia: Custodiol HTK Solution | 18.8 |
| Cold Blood Cardioplegia | 22.2 |
Troponin I values, difference from baseline 7 hours post surgery (NCT01681095)
Timeframe: Baseline and 7 hours post surgery
| Intervention | ng/mL (Median) |
|---|---|
| Cardioplegia: Custodiol HTK Solution | 9.65 |
| Cold Blood Cardioplegia | 10.15 |
LV ejection fraction by TTE, difference from baseline at 24 hours post surgery (NCT01681095)
Timeframe: Baseline and 24 hours post surgery
| Intervention | % LV volume (Mean) |
|---|---|
| Cardioplegia: Custodiol HTK Solution | -0.06 |
| Cold Blood Cardioplegia | 1.9 |
Total time in minutes on any vasopressor or inotropic agent, including norepinephrine, epinephrine, vasopressin, milrinone, dobutamine, dopamine and/or neo-synephrine (NCT01681095)
Timeframe: up to 36 hours post procedure
| Intervention | minutes (Median) |
|---|---|
| Cardioplegia: Custodiol HTK Solution | 340 |
| Cold Blood Cardioplegia | 582 |
Duration of stay in ICU, from ICU admission to ICU discharge (NCT01681095)
Timeframe: up to 100 days after admission
| Intervention | days (Median) |
|---|---|
| Cardioplegia: Custodiol HTK Solution | 3 |
| Cold Blood Cardioplegia | 3 |
Number or participants fulfilling at least two of the following 3 criteria: (1) CK-MB of 100 ug/L or more and/or troponin-I of 3.0 ug/L or more, (2) appearance of new postoperative Q waves on the EKG of more than 0.03 seconds, and (3) a new hypokinetic or akinetic area in the left or right ventricle by echocardiography. (NCT01681095)
Timeframe: up to 36 hours post procedure
| Intervention | participants (Number) |
|---|---|
| Cardioplegia: Custodiol HTK Solution | 0 |
| Cold Blood Cardioplegia | 0 |
Number of patients receiving vasopressor or inotropic infusion for greater than 20 minutes in the operating room, including norepinephrine, epinephrine, vasopressin, milrinone, dobutamine, dopamine and/or neo-synephrine. (NCT01681095)
Timeframe: during operative procedure
| Intervention | participants (Number) |
|---|---|
| Cardioplegia: Custodiol HTK Solution | 47 |
| Cold Blood Cardioplegia | 43 |
time in hours from intubation to extubation, with intervening transport to the cardiac critical care unit. (NCT01681095)
Timeframe: up to 36 hours post procedure
| Intervention | hours (Median) |
|---|---|
| Cardioplegia: Custodiol HTK Solution | 10.5 |
| Cold Blood Cardioplegia | 11.4 |
2 trials available for procaine and Injury, Myocardial Reperfusion
| Article | Year |
|---|---|
Procaine and timing of aortic declamping affect ventricular reperfusion fibrillation.
Topics: Adult; Aged; Cardioplegic Solutions; Coronary Artery Bypass; Coronary Disease; Double-Blind Method; | 1996 |
[Efficacy of terminal warm blood cardioplegia in combination with Bretschneider-HTK solution for myocardial protection].
Topics: Aged; Blood; Cardioplegic Solutions; Cardiopulmonary Bypass; Female; Glucose; Heart Arrest, Induced; | 1999 |
28 other studies available for procaine and Injury, Myocardial Reperfusion
| Article | Year |
|---|---|
Astragalin and dihydromyricetin as adjuncts to histidine‑tryptophan‑ketoglutarate cardioplegia enhances protection during cardioplegic arrest.
Topics: Animals; Apoptosis; Biomarkers; Cardioplegic Solutions; Cardiotonic Agents; Cytokines; Disease Model | 2018 |
The efficiency of heart protection with HTK or HTK-N depending on the type of ischemia.
Topics: Animals; Calcium; Cardioplegic Solutions; Female; Gap Junctions; Glucose; Guinea Pigs; Heart Arrest, | 2019 |
Antiarrhythmic effect of sevoflurane as an additive to HTK solution on reperfusion arrhythmias induced by hypothermia and ischaemia is associated with the phosphorylation of connexin 43 at serine 368.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Connexin 43; Disease Models, Animal; Gap Junc | 2019 |
Design and Development of Novel 1,3,5-Triazine-Procaine Derivatives as Protective Agent against Myocardial Ischemia/Reperfusion Injury via Inhibitor of Nuclear Factor-κB.
Topics: Animals; Cardiotonic Agents; Catalase; Glutathione; Glutathione Peroxidase; Myocardial Reperfusion I | 2019 |
Myocardial protection in donor heart preservation: a comparison between Bretschneider's histidine-tryptophan-ketoglutarate solution and cold blood cardioplegia.
Topics: Adult; Cardioplegic Solutions; Chi-Square Distribution; Cold Temperature; Female; Glucose; Heart Arr | 2014 |
Acute hemodynamic effects of angiotensin- converting enzyme inhibition after prolonged cardiac arrest with Bretschneider's solution.
Topics: Adenosine Triphosphate; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhib | 2014 |
Histidine-tryptophan-ketoglutarate solution with added ebselen augments myocardial protection in neonatal porcine hearts undergoing ischemia/reperfusion.
Topics: Animals; Antioxidants; Azoles; Glucose; Heart; Heart Arrest, Induced; Isoindoles; Mannitol; Myocardi | 2015 |
Mechanoenergetic function and troponin T release following cardioplegic arrest induced by St Thomas' and histidine-tryptophan-ketoglutarate cardioplegia--an experimental comparative study in pigs.
Topics: Animals; Bicarbonates; Biomarkers; Calcium Chloride; Cardioplegic Solutions; Cardiopulmonary Bypass; | 2009 |
Deferoxamine, the newly developed iron chelator LK-614 and N-alpha-acetyl-histidine in myocardial protection.
Topics: Animals; Cold Ischemia; Deferoxamine; Glucose; Heart Transplantation; Histidine; Hydroxamic Acids; I | 2010 |
Superior myocardial preservation with HTK solution over Celsior in rat hearts with prolonged cold ischemia.
Topics: Adenosine Triphosphate; AMP-Activated Protein Kinases; Animals; Apoptosis; Cold Ischemia; Creatine K | 2010 |
Polymerised placenta haemoglobin attenuates cold ischaemia/reperfusion injury in isolated rat heart.
Topics: Animals; Apoptosis; Cold Ischemia; Female; Glucose; Hemoglobins; Interleukin-1beta; Mannitol; Myocar | 2011 |
Cardioprotective effects of low-dose cyclosporin A added to histidine-tryptophan-ketoglutarate cardioplegia solution prior to total myocardial ischemia: an in vitro rabbit heart study.
Topics: Adenosine Triphosphate; Animals; Cardioplegic Solutions; Cardiotonic Agents; Cyclosporine; Glucose; | 2011 |
Cardioprotective effect of a hemoglobin-based oxygen carrier on cold ischemia/reperfusion injury.
Topics: Animals; Blood Substitutes; Cold Ischemia; Down-Regulation; Glucose; Hemoglobins; Interleukin-6; Man | 2011 |
Custodiol versus blood cardioplegia in complex cardiac operations: an Australian experience.
Topics: Aged; Australia; Cardiac Surgical Procedures; Cardiotonic Agents; Chi-Square Distribution; Female; G | 2013 |
Deleterious effect of hypothermia in myocardial protection against cold ischemia: a comparative study in isolated rat hearts.
Topics: Animals; Bicarbonates; Calcium Chloride; Cardioplegic Solutions; Cold Ischemia; Disaccharides; Edema | 2012 |
New HTK-N46B cardioplegia provides superior protection during ischemia/reperfusion in failing hearts.
Topics: Animals; Biomarkers; Cardiac Surgical Procedures; Cardioplegic Solutions; Disease Models, Animal; Gl | 2013 |
Initial reperfusion with magnesium after cardioplegic arrest attenuates myocardial reperfusion injury.
Topics: Animals; Bicarbonates; Calcium Chloride; Cardioplegic Solutions; Creatine Kinase; Glucose; Guinea Pi | 2002 |
Cardioprotection by sevoflurane against reperfusion injury after cardioplegic arrest in the rat is independent of three types of cardioplegia.
Topics: Adenosine; Allopurinol; Anesthetics, Inhalation; Animals; Cardioplegic Solutions; Glucose; Glutathio | 2002 |
Influence of superoxide dismutase on reperfusion injury in donor hearts preserved with Bretschneider-HTK cardioplegic solution.
Topics: Animals; Dogs; Glucose; Heart Transplantation; Inclusion Bodies; Mannitol; Mitochondria, Heart; Myoc | 1993 |
Myocardial protection during prolonged ischaemic cardiac arrest: experimental evaluation of three crystalloid cardioplegic solutions.
Topics: Animals; Bicarbonates; Calcium Chloride; Cardioplegic Solutions; Electrolytes; Evaluation Studies as | 1994 |
Effect of HTK solution for myocardial preservation.
Topics: Animals; Cardiac Surgical Procedures; Cardioplegic Solutions; Glucose; Heart; Heart Arrest, Induced; | 1996 |
Enflurane and isoflurane, but not halothane, protect against myocardial reperfusion injury after cardioplegic arrest with HTK solution in the isolated rat heart.
Topics: Anesthetics, Inhalation; Animals; Cardioplegic Solutions; Creatine Kinase; Enflurane; Glucose; Halot | 1998 |
Comparison of clinical outcome between histidine-triptophan-ketoglutalate solution and cold blood cardioplegic solution in mitral valve replacement.
Topics: Blood; Cardioplegic Solutions; Case-Control Studies; Female; Glucose; Heart Valve Prosthesis Implant | 1998 |
Beneficial effects of sevoflurane and desflurane against myocardial reperfusion injury after cardioplegic arrest.
Topics: Anesthetics, Inhalation; Animals; Creatine Kinase; Desflurane; Diastole; Glucose; Heart Arrest, Indu | 1999 |
Postischemic cardiac function recovery in the isolated rat heart: effects of adenosine deaminase and nucleoside transport inhibition.
Topics: Adenine; Adenosine Deaminase; Affinity Labels; Animals; Cardioplegic Solutions; Disease Models, Anim | 2000 |
Different preservation of myocardial capillary endothelial cells and cardiomyocytes during and after cardioplegic ischemia (25 degrees C) of canine hearts.
Topics: Animals; Bicarbonates; Calcium Chloride; Cardioplegic Solutions; Dogs; Endothelium, Vascular; Female | 2002 |
Patterns of structural deterioration due to ischemia in Purkinje fibres and different layers of the working myocardium.
Topics: Animals; Bicarbonates; Calcium Chloride; Cardioplegic Solutions; Dogs; Endocardium; Glucose; Heart A | 1991 |
[Ischemic-reperfusion injury of the heart: comparison of intra- and extracellular types of cardioplegic solutions].
Topics: Animals; Bicarbonates; Calcium Chloride; Cardioplegic Solutions; Glucose; In Vitro Techniques; Magne | 1989 |